

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/591,923-Conf. #5393
				Filing Date	June 21, 2007
				First Named Inventor	Daniel J. Rader
				Art Unit	1614
				Examiner Name	K. E. Weddington
Sheet	1	of	3	Attorney Docket Number	AGP-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-4,716,175	12-29-1987	Hoefle et al.	
	A2*	US-5,015,644	05-14-1991	Roth et al.	
	A3*	US-5,026,554	06-25-1991	Bartizal et al.	
	A4*	US-5,510,379	04-23-1996	Lee et al.	
	A5*	US-6,121,283	09-19-2000	Chang et al.	
	A6*	US-6,140,343	10-31-2000	DeNinno et al.	
	A7*	US-7,358,254	04-15-2008	Robl et al.	
	A8*	US-7,394,501	07-01-2008	Iwata et al.	
	A9*	US-2003/0153541	08-14-2003	Dudley et al.	
	A10*	US-2006/0160834	07-20-2006	Fong et al.	
	A11*	US-2006/0166999	07-27-2006	Grutzmann et al.	
	A12*	US-2007/0098778	05-03-2007	Borsadia	
	A13*	US-2007/0099884	05-03-2007	Erondu et al.	
	A14*	US-2008/0016127	01-17-2008	Field	
	A15*	US-2008/0033019	02-07-2008	Stamler	
	A16*	US-2008/0051427	02-28-2008	Schuckler	
	A17*	US-2008/0103122	05-01-2008	Veltri	
	A18*	US-2008/0161279	07-03-2008	Wisler	
	A19*	US-2008/0175864	07-24-2008	Ye et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-96/026948-A1	09-06-1996	Pharmacia Spa et al.		
	B2	WO-05/033100-A1	04-14-2005	Lipideon Biotechnology Ag et al.		
	B3	WO-07/047724	04-26-2007	Wisler		
	B4	WO-08/012056	01-31-2008	Zeiss Carl Microimaging		
	B5	WO-08/021353	02-21-2008	Luo Guangxiang		
	B6	WO-08/030382	03-13-2008	Schering Corp		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/591,923-Conf. #5393
				Filing Date	June 21, 2007
				First Named Inventor	Daniel J. Rader
				Art Unit	1614
				Examiner Name	K. E. Weddington
				Attorney Docket Number	AGP-002
Sheet	2	of	3		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B7	WO-08/072061	06-19-2008	Pfizer Prod Inc.		
	B8	WO-08/075949	06-26-2008	Stichting Top Inst		
	B9	WO-08/079398-A1	07-03-2008	Aegerion Pharmaceuticals Inc et al.		
	B10	WO-08/090198	07-31-2008	Janssen Pharmaceutica NV		
	B11	WO-08/115574	09-25-2008	Reliant Pharmaceuticals, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. *Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/591,923-Conf. #5393
				Filing Date	June 21, 2007
				First Named Inventor	Daniel J. Rader
				Art Unit	1614
				Examiner Name	K. E. Weddington
Sheet	3	of	3	Attorney Docket Number	AGP-002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Aggarwal, et al; BMC Cardiovasc. Disord. 27;5(1):30 (2005)	
	C2	Chandler, et al., J. Lipid. Res. 44(10):1887-901 (2003)	
	C3	Cuchel et al., "Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia," N Engl J Med., (2007); 356:148-156.	
	C4	Funatsu et al. "Atorvastatin Increases Hepatic Fatty Acid Beta-Oxidation in Sucrose-Fed Rats: Comparison with an MTP Inhibitor." Eur. J. Pharm. 2002 455:161-167	
	C5	Li, et al., "Discovery of Potent and Orally Active MTP Inhibitors as Potential Anti-Obesity Agents," Bioorganic & Medicinal Chemistry Letters, Oxford, GB, Vol. 16, No. 11, 1 June 2006, pp. 3039-3042	
	C6	Looije, Norbert A., et al., "Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) Reduces Plasma Cholesterol Concentration, Body Weight and Abdominal Fat Gain Within a Dietary-Induced Obese Mouse Model," Journal of Pharmacy & Pharmaceutical Sciences: A Publication of the Canadian Society for Pharmaceutical Sciences, Vol. 8, No. 3, 2005, pp. 400-408	
	C7	Samaha, et al., "Inhibition Of Microsomal Triglyceride Transfer Protein Alone Or With Ezetimibe In Patients With Moderate Hypercholesterolemia," Nature Clinical Practice, (2008) , pp. 1-9, Nature Publishing Group	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.